<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BROMDAY- bromfenac sodium solution/ drops </strong><br>Unit Dose Services<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Bromday™ (bromfenac ophthalmic solution) 0.09% safely and effectively.  See full prescribing information for Bromday. Bromday  (bromfenac ophthalmic solution) 0.09% Initial U.S. Approval: 1997
        <br><br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Bromday is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction .
                                    <span class="Bold"><a href="#i4i_indications_id_abf2bf44-cca0-404f-8605-94db94bfe480">(1)</a></span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop into the affected eye(s) once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery
                                    <span class="Bold">.
                                        <a href="#i4i_section_id_f0ccad64-59b2-4809-bc95-9c695ceba497">(2.1)</a></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Topical ophthalmic solution: bromfenac 0.09%
                                    <span class="Bold">.
                                        <a href="#i4i_dosage_form_strength_id_996da360-828e-4142-b4f2-2177c9ee34e2">(3)</a></span> </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>
                                        <span class="Bold"><a href="#i4i_section_id_80219bb1-5467-4706-b6a4-5681fdf88f94">(5.1)</a></span>
</li>
<li>Slow or Delayed Healing
                                        <span class="Bold"><a href="#i4i_section_id_51555dfc-f930-4e24-a3f8-4a1bf36c79ac">(5.2)</a></span>
</li>
<li>Potential for cross-sensitivity
                                        <span class="Bold"><a href="#i4i_section_id_9e7e0c19-9222-478e-aa13-455184816df8">(5.3)</a></span>
</li>
<li>Increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues
                                        <span class="Bold"><a href="#i4i_section_id_f70ac7bf-d093-4502-96a2-7ae7555ff7af">(5.4)</a></span>
</li>
<li>Corneal effects including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>
                                        <span class="Bold"><a href="#i4i_section_id_5f8fbb2e-9722-4148-b9f1-ed23ee02af51">(5.5)</a></span>
</li>
<li>Contact Lens Wear
                                        <span class="Bold"><a href="#i4i_section_id_afd53186-13ef-4ee2-b29a-8d1bebec5440">(5.6)</a></span>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> and <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> (including burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>) .
                                    <span class="Bold"><a href="#i4i_section_id_5036f3e8-69c6-4be5-939e-ea22e20441b2">(6.1)</a></span><br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ISTA Pharmaceuticals, Inc. at 1-877-788-2020, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Use with Other Topical Ophthalmic Medications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Slow or Delayed Healing</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Potential for Cross-Sensitivity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> and Corneal Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Contact Lens Wear</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1 Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery</a></h2>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Slowed or Delayed Healing</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 Concomitant Use of Contact Lenses</a></h2>
<h2><a href="#section-13.4" class="toc">17.4 Concomitant Topical Ocular Therapy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_abf2bf44-cca0-404f-8605-94db94bfe480"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Bromday™ (bromfenac ophthalmic solution) 0.09% is indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f07f219a-ca6d-488b-83fa-b2ea642cbc58"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0ccad64-59b2-4809-bc95-9c695ceba497"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">For the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction, one drop of Bromday ophthalmic solution should be applied to the affected eye(s) once daily beginning 1 day prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28b3bfb0-48d2-4473-a78d-ef8c1442b5d7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Use with Other Topical Ophthalmic Medications</h2>
<p class="First">Bromday ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.  Drops should be administered at least 5 minutes apart.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_996da360-828e-4142-b4f2-2177c9ee34e2"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Topical ophthalmic solution: bromfenac 0.09%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_10bb991c-7c2e-44b7-abbe-688e08d5720d"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_a76984fc-c00a-45d0-993c-435dfb84e8b9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80219bb1-5467-4706-b6a4-5681fdf88f94"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_51555dfc-f930-4e24-a3f8-4a1bf36c79ac"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Slow or Delayed Healing</h2>
<p class="First">All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e7e0c19-9222-478e-aa13-455184816df8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Potential for Cross-Sensitivity</h2>
<p class="First">There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f70ac7bf-d093-4502-96a2-7ae7555ff7af"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></h2>
<p class="First">With some NSAIDs, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.</p>
<p>It is recommended that Bromday ophthalmic solution be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f8fbb2e-9722-4148-b9f1-ed23ee02af51"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> and Corneal Reactions</h2>
<p class="First">Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> or <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.</p>
<p>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface diseases (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</p>
<p>Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_afd53186-13ef-4ee2-b29a-8d1bebec5440"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Contact Lens Wear</h2>
<p class="First">Bromday should not be administered while wearing contact lenses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_3994ab5f-c6d4-423d-8c8b-878cd8fd5ada"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5036f3e8-69c6-4be5-939e-ea22e20441b2"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">The most commonly reported adverse experiences reported following use of bromfenac after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery include:  abnormal sensation in eye, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> (including burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>), <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>.  These events were reported in 2-7% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94088857-3d9e-4c63-b479-8cbe51355c7c"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">The following events have been identified during post-marketing use of bromfenac ophthalmic solution 0.09% in clinical practice.  Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution 0.09% or a combination of these factors, include <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, and epithelial breakdown. [ ]
                                    <span class="Italics">see Warnings and Precautions</span><a href="#i4i_warnings_precautions_id_a76984fc-c00a-45d0-993c-435dfb84e8b9">(5)</a></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_7b101aaf-ab48-4878-83ef-5d8573eee5f1"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6a1dce52-34e0-4879-8b1d-395ce52f207f"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post-implantation loss.
                                    <span class="Bold">Teratogenic Effects: Pregnancy Category C.</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold">Nonteratogenic Effects:</span></p>
<p>Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of Bromday ophthalmic solution during late pregnancy should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_51a611e7-8029-463e-b236-4885533efa84"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Caution should be exercised when Bromday is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ccf4c0d0-cfd2-4252-bd35-d343122c0e46"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy in pediatric patients below the age of 18 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9abde8ff-db2a-458a-86d3-50e2ee725744"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There is no evidence that the efficacy or safety profiles for Bromday differ in patients 65 years of age and older compared to younger adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1f6e9905-a7b3-4ed1-89f7-09f9ee55d41a"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Bromday™ (bromfenac ophthalmic solution) 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use.  Each mL of Bromday  contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid).  Bromfenac sodium is designated chemically as sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, with an empirical formula of C H BrNNaO • 1½H O.  The structural formula for bromfenac sodium is:
                            <span class="Sub">15</span><span class="Sub">11</span><span class="Sub">3</span><span class="Sub">2</span></p>
<div class="Figure"><img alt="chemical structure for bromfenac sodium hydrate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=234a2447-90a7-4b8a-a344-7eef1e5daa6a&amp;name=83641d64-f709-4330-bb0a-7b8c1c88f85e-01.jpg"></div>
<p>Bromfenac sodium is a yellow to orange crystalline powder.  The molecular weight of bromfenac sodium is 383.17.  Bromday ophthalmic solution is supplied as a sterile aqueous 0.09% solution, with a pH of 8.3.  The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of Bromday ophthalmic solution is approximately 300 mOsmol/kg.</p>
<p>: bromfenac sodium hydrate 0.1035% :  benzalkonium chloride (0.05 mg/mL) :  boric acid, disodium edetate (0.2 mg/mL), polysorbate 80 (1.5 mg/mL), povidone (20 mg/mL), sodium borate, sodium sulfite anhydrous (2 mg/mL), sodium hydroxide to adjust pH and water for injection, USP.
                            <span class="Bold">Each mL of Bromday ophthalmic solution contains: Active
                                <br></span><br><span class="Bold">Preservative</span><br><span class="Bold">Inactives</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_5e10512a-46ef-426a-b187-7d106f950282"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_1a88857e-5f2c-4bb9-80b5-3012252304a9"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.</p>
<p>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3635a265-b335-4733-81d9-55efa16bd0bf"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The plasma concentration of bromfenac following ocular administration of 0.09% Bromday (bromfenac ophthalmic solution) in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_76291a18-356e-4ef7-ad77-78d5ffcf3d31"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d183779d-bb9d-470d-9030-82f3326e712e"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence.</p>
<p>Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.</p>
<p>Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_f3c5f80e-7472-42e3-996d-04d97c7afbef"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9db7596e-c3b4-4db3-9510-8bb61003ee0a"></a><a name="section-11.1"></a><p></p>
<h2>14.1 Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery</h2>
<p class="First">Clinical efficacy was evaluated in three randomized, double-masked, placebo-controlled trials in which subjects requiring <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery were assigned to Bromday or placebo.  Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days.  The primary endpoint was clearing of ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by day 15.  An additional efficacy endpoint was the number of patients who were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> free on day 1 after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
<p>In 2 of the 3 studies, Bromday ophthalmic solution had statistically significant higher incidence of completely clearing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (46-47% vs. 25-29%) and also had a statistically significant higher incidence of subjects that were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> free at day 1 post <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery (83-89% vs. 51-71%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8755d3cf-b962-4070-8be3-e4ec20d8b2c5"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:50436-6301-0 in a BOTTLE, DROPPER of 1.7 SOLUTION/ DROPSS</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ae826948-8cb2-46d3-bb12-5cce51097ef9"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7548a09-4137-4287-aad6-d787ac5e6cbc"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Slowed or Delayed Healing</h2>
<p class="First">Patients should be advised of the possibility that slow or delayed healing may occur while using NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c07da7f-ec00-4d91-89ff-279f4909802c"></a><a name="section-13.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</h2>
<p class="First">Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8fb3c91-c5cb-469e-8774-3d52f3468618"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Concomitant Use of Contact Lenses</h2>
<p class="First">Contact lenses should not be worn during the use of this product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5f0d449-f149-4123-aacc-ae89abfc93ab"></a><a name="section-13.4"></a><p></p>
<h2>17.4 Concomitant Topical Ocular Therapy</h2>
<p class="First">If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">©ISTA Pharmaceuticals , Inc.
                                        <span class="Sup">®</span></span></p>
<p>Manufactured for: ISTA Pharmaceuticals, Inc. Irvine, CA  92618
                                    <br><br></p>
<p>By: Bausch &amp; Lomb Incorporated Tampa, FL 33637
                                    <br><br></p>
<p>Under license from: Senju Pharmaceuticals Co., Ltd. Osaka, Japan 541-0046
                                    <br><br></p>
<p>® and ™ marks owned by ISTA Pharmaceuticals, Inc.
                                    <br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0004ac09-b644-41ce-a0c6-835b2f3cc319"></a><a name="section-14"></a><p></p>
<h1>BROMDAY (BROMFENAC) SOLUTION/ DROPS</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=234a2447-90a7-4b8a-a344-7eef1e5daa6a&amp;name=50436-6301.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BROMDAY 		
					</strong><br><span class="contentTableReg">bromfenac solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50436-6301(NDC:67425-999)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BROMFENAC SODIUM</strong> (BROMFENAC) </td>
<td class="formItem">BROMFENAC</td>
<td class="formItem">0.9 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BORATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM SULFITE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50436-6301-0</td>
<td class="formItem">1.7 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021664</td>
<td class="formItem">09/20/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Unit Dose Services
							(831995316)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Unit Dose Services (831995316)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unit Dose Services</td>
<td class="formItem"></td>
<td class="formItem">831995316</td>
<td class="formItem">REPACK(50436-6301)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>323f622f-6ffb-4557-af9d-4ef6f40541e8</div>
<div>Set id: 234a2447-90a7-4b8a-a344-7eef1e5daa6a</div>
<div>Version: 2</div>
<div>Effective Time: 20100914</div>
</div>
</div> <div class="DistributorName">Unit Dose Services</div></p>
</body></html>
